CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein

Vaccine

Volumn 28, Issue 41, 2010, Pages 6666-6674

  Zhao, Kai ^a   Yang, Binyan ^a   Xu, Yanquan ^a   Wu, Changyou ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

0201; CTL; HLA A; SARS CoV; Vaccine

Indexed keywords

CD45RB ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A 0201 RESTRICTED PEPTIDE P19; HLA A 0201 RESTRICTED PEPTIDE P20; HLA A 0201 RESTRICTED PEPTIDE P21; HLA A 0201 RESTRICTED PEPTIDE P22; HLA A 0201 RESTRICTED PEPTIDE P23; HLA A ANTIGEN; INTERLEUKIN 2; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; PEPTIDE; PLASMID DNA; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SARS CORONAVIRUS; TRANSGENIC MOUSE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 77956478136     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.013     Document Type: Article

References (43)

1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348(20):1953-1966.
2. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003, 348(20):1967-1976.
3. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361(9366):1319-1325.
4. Normile D. Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004, 304(5671):659-661.
5. Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004, 4(2):64.
6. Fleck F. SARS virus returns to China as scientists race to find effective vaccine. Bull World Health Organ 2004, 82(2):152-153.
7. Paterson R. SARS returns to China. Lancet Infect Dis 2004, 4(2):64.
8. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300(5624):1394-1399.
9. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 2003, 300(5624):1399-1404.
10. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004, 78(12):6134-6142.
11. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004, 101(26):9804-9809.
12. Huang J., Ma R., Wu C.Y. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006, 24(23):4905-4913.
13. Pei J., Briles W.E., Collisson E.W. Memory T cells protect chicks from acute infectious bronchitis virus infection. Virology 2003, 306(2):376-384.
14. Seo S.H., Wang L., Smith R., Collisson E.W. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol 1997, 71(10):7889-7894.
15. Ostler T., Davidson W., Ehl S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol 2002, 32(8):2117-2123.
16. Ostler T., Ehl S. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity. Eur J Immunol 2002, 32(9):2562-2569.
17. Yang L.T., Peng H., Zhu Z.L., Li G., Huang Z.T., Zhao Z.X., et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 2006, 120(2):171-178.
18. Huang J., Cao Y., Du J., Bu X., Ma R., Wu C. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 2007, 25(39-40):6981-6991.
19. Sidney J., Grey H.M., Kubo R.T., Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996, 17(6):261-266.
20. Lin M., Tseng H.K., Trejaut J.A., Lee H.L., Loo J.H., Chu C.C., et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003, 4:9.
21. Tsao Y.P., Lin J.Y., Jan J.T., Leng C.H., Chu C.C., Yang Y.C., et al. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006, 344(1):63-71.
22. Wang B., Chen H., Jiang X., Zhang M., Wan T., Li N., et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004, 104(1):200-206.
23. Lv Y., Ruan Z., Wang L., Ni B., Wu Y. Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV. BMC Immunol 2009, 10:61.
24. Zhou M., Xu D., Li X., Li H., Shan M., Tang J., et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 2006, 177(4):2138-2145.
25. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428(6982):561-564.
26. Taylor R. Bioinformatics and molecular analysis section (BIMAS) HLA peptide bingding predictions ; 2000. http://bimas.dcrt.nih.gov/molbio/hla_bind/index.htm.
27. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50(3-4):213-219.
28. Passoni L., Scardino A., Bertazzoli C., Gallo B., Coluccia A.M., Lemonnier F.A., et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002, 99(6):2100-2106.
29. Ishioka G.Y., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999, 162(7):3915-3925.
30. Arichi T., Saito T., Major M.E., Belyakov I.M., Shirai M., Engelhard V.H., et al. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A 2000, 97(1):297-302.
31. Cao X., Zhang W., He L., Xie Z., Ma S., Tao Q., et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998, 161(11):6238-6244.
32. Berenzon D., Schwenk R.J., Letellier L., Guebre-Xabier M., Williams J., Krzych U. Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J Immunol 2003, 171(4):2024-2034.
33. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78(11):5535-5545.
34. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281(1-2):65-78.
35. Masopust D., Vezys V., Usherwood E.J., Cauley L.S., Olson S., Marzo A.L., et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 2004, 172(8):4875-4882.
36. Herd K.A., Mahalingam S., Mackay I.M., Nissen M., Sloots T.P., Tindle R.W. Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol 2006, 80(4):2034-2044.
37. Johnston R.E. A candidate vaccine for severe acute respiratory syndrome. N Engl J Med 2004, 351(8):827-828.
38. Kamath A., Woodworth J.S., Behar S.M. Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 2006, 177(9):6361-6369.
39. Wolint P., Betts M.R., Koup R.A., Oxenius A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med 2004, 199(7):925-936.
40. Qu D., Lanier G., Yuan Z.H., Wen Y.M., Howard C.R., Ahmed R. Localization of CD8+ cells specific for hepatitis B virus surface protein in the liver of immunized mice. J Med Virol 2008, 80(2):225-232.
41. Zimmerman C., Brduscha-Riem K., Blaser C., Zinkernagel R.M., Pircher H. Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J Exp Med 1996, 183(4):1367-1375.
42. Walker P.R., Ohteki T., Lopez J.A., MacDonald H.R., Maryanski J.L. Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol 1995, 155(7):3443-3452.
43. Meraldi V., Romero J.F., Kensil C., Corradin G. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 2005, 23(21):2801-2812.